Results 161 to 170 of about 35,534 (303)

A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells

, 2021
Reine Hanna, Jad Abdallah, Thamara J. Abouantoun   +2 more
openalex   +1 more source

Aurora-A prevents transcription-replication conflicts in MYCN-amplified neuroblastoma [PDF]

, 2021
Isabelle Röschert
openalex   +1 more source

MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription.

PLoS Biology
MYCN activates canonical MYC targets involved in ribosome biogenesis, protein synthesis, and represses neuronal differentiation genes to drive oncogenesis in neuroblastoma (NB). How MYCN orchestrates global gene expression remains incompletely understood.
Zhihui Liu, Xiyuan Zhang, Man Xu, Jason J Hong, Amanda Ciardiello, Haiyan Lei, Jack F Shern, Carol J Thiele   +7 more
doaj   +1 more source

E2F Proteins Regulate MYCN Expression in Neuroblastomas [PDF]

, 2003
Verena Strieder, W. Lutz
openalex   +1 more source

MYCN in neuroblastoma: The kings' new clothes and drugs

EJC Paediatric Oncology
Deregulated levels of the MYCN oncogene contribute to the tumorigenesis of several human tumors including neuroblastoma. MYCN amplification classifies neuroendocrine tumors as high-risk and as a consequence is an unfavorable prognostic factor.
Mareike Müller, Katrin Trunk, Daniel Fleischhauer, Gabriele Büchel   +3 more
doaj   +1 more source

Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival [PDF]

, 2020
Simon Keane, Sophie Améen, Angelica Lindlöf, Katarina Ejeskär   +3 more
openalex   +1 more source

ALK upregulates POSTN and WNT signaling to drive neuroblastoma

Cell Reports
Summary: Neuroblastoma is the most common extracranial solid tumor of childhood. While MYCN and mutant anaplastic lymphoma kinase (ALKF1174L) cooperate in tumorigenesis, how ALK contributes to tumor formation remains unclear.
Miller Huang, Wanqi Fang, Alvin Farrel, Linwei Li, Antonios Chronopoulos, Nicole Nasholm, Bo Cheng, Tina Zheng, Hiroyuki Yoda, Megumi J. Barata, Tania Porras, Matthew L. Miller, Qiqi Zhen, Lisa Ghiglieri, Lauren McHenry, Linyu Wang, Shahab Asgharzadeh, JinSeok Park, W. Clay Gustafson, Katherine K. Matthay, John M. Maris, William A. Weiss   +21 more
doaj   +1 more source

Figure S6 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma [PDF]

, 2023
Zhang’E Choo, Xiaoying Koh, Megan Rui En Wong, Ruth Minothini Ashokan, Nurul Suhana Binte Ali Ahamed, CongBao Kang, Chik Hong Kuick, Kenneth Tou En Chang, Sarit Larisch, Amos Hong Pheng Loh, Zhi Xiong Chen   +10 more
openalex   +1 more source

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

Pharmacological Research
Current treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates.
Laura Grunewald, Lena Andersch, Konstantin Helmsauer, Silke Schwiebert, Anika Klaus, Anton G. Henssen, Teresa Straka, Marco Lodrini, Sebastian G. Wicha, Steffen Fuchs, Falk Hertwig, Frank Westermann, Alice Vitali, Carlotta Caramel, Gabriele Büchel, Martin Eilers, Kathy Astrahantseff, Angelika Eggert, Uta E. Höpken, Johannes H. Schulte, Thomas Blankenstein, Kathleen Anders, Annette Künkele   +22 more
doaj   +1 more source

Prostaglandin E ₂ promotes MYCN non‐amplified neuroblastoma cell survival via β‐catenin stabilization [PDF]

, 2014
Sepp R. Jansen, Rian Holman, Ilja Hedemann, Ewoud Frankes, Carolina R.S. Elzinga, Wim Timens, Reinoud Gosens, Eveline S. de Bont, Martina Schmidt   +8 more
openalex   +1 more source